Key companies, such as CSL Behring, Equillium, Biocon, and medac, are advancing their assets through late-stage graft versus host disease clinical trials, driving innovation in the graft versus host ...

Key companies, such as CSL Behring, Equillium, Biocon, and medac, are advancing their assets through late-stage graft versus host disease clinical trials, driving innovation in the graft versus ...

Equillium Reports Positive Phase 2 Results for Itolizumab in Ulcerative Colitis, Shares Surge Itolizumab achieved a clinical remission rate of 23.3% in ulcerative colitis patients. GuruFocus.com ...

With the rapid evolution of precision medicine, diagnostic, and therapeutic strategies for lupus nephritis (LN) are progressively shifting towards greater personalisation and accuracy. On the ...